PEAK6 Investments’s PMV Pharmaceuticals PMVP Stock Holding History

PEAK6 Investments’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32,500	Closed	-$200K	–	4703
2023 Q3	$200K	Buy	+32,500	New	+$223K	﹤0.01%	3069

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PEAK6 Investments's PMVP Position: Q4 2023 in Review

PEAK6 Investments sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 32,500 shares — an estimated $200K sold.

PEAK6 Investments first reported a position in PMVP in Q3 2023 and held it in 1 quarter. The position peaked at $200K in Q3 2023. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

PEAK6 Investments reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
PEAK6 Investments sold 32,500 PMV Pharmaceuticals shares in Q4 2023, an estimated $200K.
PEAK6 Investments first reported a position in PMV Pharmaceuticals in Q3 2023 and held it in 1 quarter.
PEAK6 Investments's PMV Pharmaceuticals position peaked at $200K in Q3 2023.
98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.